These therapies require specialized sites, recruitment strategies and clinical development partners experienced in delivery of these complex programs.

TORONTO (PRWEB)
May 25, 2023

CAR T-cell therapies are fundamentally changing the landscape of cancer treatment. Successful commercialization of multiple CAR T treatments, plus continued advancements in the technologies, combine to make this a very active segment of drug development. Despite the excitement and hope they have brought to the patient and research communities, the sponsors developing these therapeutics are encountering challenges that have delayed and seriously threatened the advancement of their programs. These therapies require specialized sites, recruitment strategies and clinical development partners experienced in delivery of these complex programs.

In this webinar, attendees will hear from speakers partnering with the sponsors developing novel CAR T therapeutics. Their corporate and personnel experience in delivering these complex programs has armed them with the lessons learned to design current and future CAR T programs in anticipation of expected challenges. Register to hear these speakers address the most common challenges and questions they hear from their CAR T sponsors.

Register today for an informative overview of how to address the challenges arising in CAR T-cell development programs. Attendees are encouraged to bring their questions, notepad and colleagues to this webinar!

Join experts from Worldwide Clinical Trials, Missy Green, MBA, Associate Director, Project Management; Jake Boyd, Director, Project Management, Oncology; Amy Raymond, PhD, PMP, Senior Director, Therapeutic Strategy Lead, Rare Diseases; and Daniel A. Perez, CCRP, Global Head, Patient Experience, Diversity & Inclusion, for the live webinar on Wednesday, June 14, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Building in Solutions for Anticipated Challenges in CAR T Development Programs.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

As the number of patients suffering from such disorders increase, so does the demand for more convenient and patient-friendly drug delivery systems.

TORONTO (PRWEB)
May 25, 2023

Chronic clinical conditions are among the leading causes of death and disability globally. Typically, individuals are required to medicate on a daily, weekly and/or monthly basis. Now more than ever, patients want to make treatment a smaller part of their life. The development and commercialization of self-administrable medicinal products outside a clinic, hospital or healthcare provider environment, is an attractive alternative for healthcare expenditure and patients because of the flexibility and desire to reduce clinic visits. As the number of patients suffering from such disorders increase, so does the demand for more convenient and patient-friendly drug delivery systems.

Over the past five years, significant improvements have been made to address dose volumes and treatment options, such as monoclonal antibody-based therapies. These treatments often have viscous, highly concentrated drug formulations that require higher doses and delivery volumes that are typically outside the range of standard syringe capabilities. Novel drug delivery technologies are being introduced, specifically, large volume, on-body drug delivery systems. The novelty of these solutions has increased the complexity of regulations and particularly how to navigate the regulations from a global perspective.

Currently, the majority of large volume wearable injectors are primarily present in North America and Europe, within which the principal global regulatory frameworks are led by, or based on, the United States and European regulations. These large-volume on-body delivery systems are typically co-packaged with pre-filled drug cartridges i.e., co-packaged combination products.

However, the pathway to approval differs between the US and Europe which can lead to diverse, complex regulatory strategies when developing a product that must meet both regulatory frameworks.

Register to learn about on-body drug delivery systems and addressing their complex global regulatory requirements.

Join experts from West Pharmaceutical Services, Inc., Paul Scannell, Director Regulatory Affairs Combination Products, EU; and Adam Coblentz, Principal, Regulatory Affairs Intelligence, for the live webinar on Thursday, June 15, 2023, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit Drug Delivery — Addressing Global Regulatory Challenges in Co-Packaged, On-Body Systems.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

PFAS – What to Know Now, and What to Expect

Companies producing, processing, distributing, and/or using these substances must be aware of global legal and scientific developments and take steps now to minimize legal, regulatory, and commercial risk.

WASHINGTON (PRWEB)
May 25, 2023

Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are attracting global legal, regulatory, commercial, and litigation attention as no other “emerging contaminant” has. Companies producing, processing, distributing, and/or using these substances must be aware of global legal and scientific developments and take steps now to minimize legal, regulatory, and commercial risk.

Bergeson & Campbell, P.C. (B&C®) and its global consulting affiliate The Acta Group (Acta®) have prepared this 20-page memorandum to assist stakeholders in preparing a PFAS gameplan. It offers a high-level outline of issues, focusing on the most significant bans and restrictions, the most impactful potential legal developments regarding PFAS, and the most important steps chemical product manufacturers should be taking now to identify, diminish, and supplant, as appropriate, PFAS in their supply chains.

We hope this information is helpful. We would be pleased to provide additional information and assist with PFAS-related scientific, regulatory, or legal questions that you may have. The full document can be downloaded at: https://www.lawbc.com/uploads/docs/PFAS_Summary.PDF

Share article on social media or email:

Healthcare Compliance Simplified

“Mental health professionals are extremely busy. This is why we aim to make compliance as quick and painless as possible. We are honored to have been selected to provide NHPA Members a streamlined way to meet their requirements” – Liam Degnan, Director of Strategic Initiatives, Compliancy Group.

GREENLAWN, N.Y. (PRWEB)
May 25, 2023

Compliancy Group is the New Hampshire Psychological Association (NHPA) Endorsed Solution for HIPAA and OSHA.

As the endorsed solution for HIPAA and OSHA compliance, Compliancy Group will provide NHPA Members an automated compliance management and tracking software at a special members-only rate. Compliancy Group’s software, the Guard, eliminates the burden of compliance in a simple, fast, and affordable way.

“Mental health professionals are extremely busy. This is why we aim to make compliance as quick and painless as possible. We are honored to have been selected to provide NHPA Members a streamlined way to meet their requirements” – Liam Degnan, Director of Strategic Initiatives, Compliancy Group.

Managing and understanding compliance can take time, making proper compliance an arduous task for busy practices. Compliancy Group’s guided software walks you through implementing an effective compliance program.

Compliancy Group Resources

HIPAA and OSHA Explained

HIPAA Compliance Checklist

HIPAA Recipe Book

About Compliancy Group

Compliancy Group’s simplified software and Compliance Success Team, remove the complexities and stress of compliance, helping healthcare professionals achieve it with ease. They give practices confidence in their compliance plan, increasing patient loyalty, and profitability of their practice while reducing risk.

As an Endorsed Solution, psychologists can be confident in their compliance program.

About the New Hampshire Psychological Association

The New Hampshire Psychological Association has been the voice of psychology in the State of New Hampshire and a steadfast champion of the mental health community. Operating from a positive core – grounded in compassion, dedication to the field, and community-mindedness – NHPA’s mission is to advance psychology as a science, as a profession, and as a means of promoting human welfare.

Locally and nationally recognized for its achievements, NHPA is an active and thriving organization for professionals with degrees in psychology and affiliated mental health fields.

Share article on social media or email:

Dr. Marta Pazos, founder of Rejuvalift Beauty, creates a skincare coaching video series.

“I’ve helped thousands with skin ailments and developed cutting-edge skincare solutions. Now, I’m taking that knowledge straight to consumers via hands-on, high-quality videos created in a simple format where I teach all courses.” – Dr. Marta Pazos, Founder of Rejuvalift Beauty.

ST. PETERSBURG, Fla. (PRWEB)
May 24, 2023

Dr. Marta Pazos, Skincare Coach, Cosmetic Chemist, and Innovator, Launches Two-Week Skin Coaching Series

The founder of Rejuvalift Beauty has helped thousands with skin ailments and has worked for the biggest cosmetic brands developing cutting-edge skincare solutions.

Dr. Marta Pazos, the founder of Rejuvalift Beauty, announces the launch of her 15-Step Skincare Rejuvenation Program, a skincare coaching series of educational videos discussing skin ailments and treatments based on her two decades in the industry. The program helps consumers become their own best solutions for treating their skin. The cosmetic brand is the first to offer a coaching program that complements its product line. The Dr. Marta Skincare Coaching series is now included for free with any Rejuvalift product purchase.

A skincare coach, cosmetic chemist and innovator, Dr. Marta gives participants an insider’s look at achieving healthier skin and uncovers tips on pro-aging techniques. She has created this one-of-a-kind curriculum to coach attendees on achieving their skincare goals in less than five minutes daily. Emmy-winning and longtime TV anchor John Biffar of PeaceVision™ studio, produced the curriculum.

“My dual experience as a researcher and product developer gives me a unique perspective on skin’s needs, with a focus on Global methods, originating in the Far East” said Dr. Marta. “I’ve helped thousands with skin ailments, worked for some of the biggest cosmetic brands globally, and developed cutting-edge skincare solutions. Now, I’m taking that knowledge straight to consumers via hands-on, high-quality videos created in a simple format where I teach all courses.”

The first five videos are now being offered on a free preview as Dr. Marta embarks on a nationwide media and promotional appearance tour. This curriculum also includes an introductory video that breaks down each subject into easy-to-understand topics for the general public. Attendees receive insight and education on caring for their skin, the body’s biggest organ, without surgery. Among the courses are:

• 
  How to Love the Skin You’re In
• Your Body’s Tools & Hormones
• Can Sleep Really Affect Your Skin?
• How the Environment Affects Your Skin
• Preventing Age Spots & Skin Cancer
• Understanding Skin Care Labels
• Is Hydrating & Moisturizing the same?

“In today’s world, we commonly have nutritional coaches, life coaches, and exercise coaches, amongst others,” added Dr. Marta. “I hope we can add a skin coach to that list. The visible results and increased knowledge are priceless.”

The course is priced at $79.00 Click here to sign up. Purchase a Rejuvalift product and receive it free with coupon code provided with online or Retail store purchase. Information on http://www.drmarta15.com or Rejuvalift Beauty, visit http://www.rejuvaliftbeauty.com.

###

About Dr. Marta:

Dr. Marta Pazos is a creator, innovator and owner of the Rejuvalift Brand, with over 20 years of experience developing specialty formulations for cosmetic and skincare products. As the lead cosmetic chemist for Rejuvalift®, Dr. Marta leverages her expertise as a formulation chemist to develop products using the minimum number of ingredients to deliver non-surgical advanced tightening and lift results.

Her passion for skincare began in her teenage years when she battled acne. She quickly learned that when you look good, you feel good. Her skincare journey and interest in chemistry led her to the U.S. from her native Spain. A Fulbright scholar, Dr. Marta earned her doctorate in Polymer Science from the University of Akron. Since then, her career has taken her to North America, Europe and Asia assignments.

Share article on social media or email:

“By launching this test, we continue down our committed path of improving patient outcomes as well as reducing overall treatment costs.” Robert Embree, CEO

IRVINE, Calif. (PRWEB)
May 24, 2023

EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the commercial availability of MetaDX™, a PCR-based assay designed to provide personalized treatment guidance for patients diagnosed with prostate cancer. Performed on biopsied prostate tissue, MetaDX™ measures the AR-V7/AR-WT Ratio to predict the patient’s resistance to Androgen Deprivation Therapy (ADT) early on in the treatment process.

“MetaDX™ addresses an important treatment decision for patients diagnosed with prostate cancer,” said Robert Embree, Chief Executive Officer, EmeritusDX. “By launching this test, we continue down our committed path of improving patient outcomes as well as reducing overall treatment costs.”

Advanced prostate cancer tends to be hormone sensitive and is often treated with androgen deprivation therapy. However, resistance to this therapy can develop through first, second, and third lines of therapy. “Our goal is to alert physicians when resistance to therapy is identified in these patients so that effective alternative treatments are provided in the earliest possible phase.”

The MetaDX™ assay is currently available from EmeritusDX’s Irvine, CA laboratory. The test is performed on paraffin embedded prostate tissue and is reported out within 3-5 days. Clients have the option of ordering this test as a reflex or on demand.

About EmeritusDX

EmeritusDX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email contact@emeritusdx.com

Share article on social media or email:

ioVet Oral rinse reduces dental plaque and gives pets healthier mouths and fresher breath

“Through an important technology breakthrough, ioVet Oral can help maintain optimum periodontal health so pets can enjoy a healthier, longer, and happy life,” Iotech International’s Chairman Herb Moskowitz, DDS.

BOCA RATON, Fla. (PRWEB)
May 24, 2023

Now, you can safely and effectively promote periodontal health in your pets thanks to ioTech International’s latest oral care offering – ioVet Oral. ioVet Oral is the first of its kind canine and feline drinking water additive periodontal product. Containing molecular iodine, ioVet Oral provides pets with clinically proven healthier mouths and fresher breath.

Proven in clinical studies, molecular iodine added to pet drinking water is significantly more effective than daily brushing in reducing dental plaque and gives your pets healthier mouths and fresher breath.

To use, simply add 1 milliliter (ml) of ioVet Oral for each 8 oz. of water to your pet’s water dish each morning. Each package provides a syringe to ensure the proper amount of ioVet Oral is dispensed into the water dish.

Among the benefits of molecular iodine for pets are:

• Safe and easy to use
• Clinically proven based on Veterinary Oral Health Council (VOHC) approved studies
• Effectively promotes gum (perio) health
• More effective than daily brushing
• Nutritional
• Does not cause microbial resistance
• Non-staining formulation
• Cost-effective preventative care
• Effective breath freshener

“Pets can’t maintain good dental hygiene on their own. Bad breath, gum infections, bone and tooth loss, can be caused by poor dental hygiene. As well, systemic diseases like diabetes and cardiovascular disease can be worsened with poor dental hygiene. Through an important technology breakthrough, ioVet Oral can help maintain optimum periodontal health so pets can enjoy a healthier, longer, and happy life,” said Iotech International’s Chairman Herb Moskowitz, DDS.

For more information, visit the company’s website at http://www.iotechinternational.com or iovetproducts.com. Contact Iotech International at support@iotechinternational.com or call 561-509-0205 ext. 5.

ioTech International is a leading developer and manufacturer of award-winning oral care products based on the Company’s patented, breakthrough molecular iodine technology. Molecular iodine is the only biocidal iodine species, accounting for all its germicidal activity. Safe and effective, molecular iodine is an essential nutrient humans require for optimal health. Products based on ioTech’s molecular iodine technology have been adopted for use in medical, dental, agricultural, consumer, and pet health markets. ioRinse, ioTech’s award-winning rinse, and other ioTech products are available at leading dental offices, the Company’s website (http://www.iotechinternational.com), and Amazon. ioVet Oral, ioTech’s pet water additive, is available at leading veterinary offices, the Company’s website, and Amazon. ioTech International headquarters are in Boca Raton, FL.

Share article on social media or email: